Jakub Hynst
Overview
Explore the profile of Jakub Hynst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Busa D, Herudkova Z, Hyl J, Vlazny J, Sokol F, Matulova K, et al.
Mol Oncol
. 2025 Jan;
PMID: 39840700
Patient-derived xenografts (PDXs) can be improved by implantation of a humanized niche. Nevertheless, the overall complexity of the current protocols, as well as the use of specific biomaterials and procedures,...
2.
Trizuljak J, Likavcova P, Stano Kozubik K, Vrzalova Z, Hynst J, Deissova T, et al.
Platelets
. 2024 Aug;
35(1):2388103.
PMID: 39212265
Inherited thrombocytopenias (ITs) encompass a group of rare disorders characterized by diminished platelet count. Recent advancements have unveiled various forms of IT, with inherited thrombocytopenia 2 (THC2) emerging as a...
3.
Mancikova V, Pesova M, Pavlova S, Helma R, Zavacka K, Hejret V, et al.
Mol Oncol
. 2022 Nov;
17(1):82-97.
PMID: 36334078
TP53 gene abnormalities represent the most important biomarker in chronic lymphocytic leukemia (CLL). Altered protein modifications could also influence p53 function, even in the wild-type protein. We assessed the impact...
4.
Romzova M, Smitalova D, Hynst J, Tom N, Loja T, Herudkova Z, et al.
Br J Haematol
. 2021 Jul;
194(3):604-612.
PMID: 34212373
There is an emerging body of evidence that patients with chronic myeloid leukaemia (CML) may carry not only breakpoint cluster region-Abelson murine leukaemia viral oncogene homologue 1 (BCR-ABL1) kinase domain...
5.
Navrkalova V, Plevova K, Hynst J, Pal K, Mareckova A, Reigl T, et al.
J Mol Diagn
. 2021 Jun;
23(8):959-974.
PMID: 34082072
B-cell neoplasms represent a clinically heterogeneous group of hematologic malignancies with considerably diverse genomic architecture recently endorsed by next-generation sequencing (NGS) studies. Because multiple genetic defects have a potential or...
6.
Bencurova P, Baloun J, Hynst J, Oppelt J, Kubova H, Pospisilova S, et al.
Sci Rep
. 2021 May;
11(1):9649.
PMID: 33958654
Temporal lobe epilepsy (TLE) is the most common epilepsy type. TLE onset in infancy aggravates features like severity, drug responsiveness, or development of comorbidities. These aggravations may arise from altered...
7.
Malcikova J, Pavlova S, Kunt Vonkova B, Radova L, Plevova K, Kotaskova J, et al.
Blood
. 2021 May;
138(25):2670-2685.
PMID: 33945616
Patients with chronic lymphocytic leukemia (CLL) bearing TP53 mutations experience chemorefractory disease and are therefore candidates for targeted therapy. However, the significance of low-burden TP53 mutations with <10% variant allele...
8.
Hynst J, Navrkalova V, Pal K, Pospisilova S
PeerJ
. 2021 Apr;
9:e10897.
PMID: 33850640
Molecular profiling of tumor samples has acquired importance in cancer research, but currently also plays an important role in the clinical management of cancer patients. Rapid identification of genomic aberrations...
9.
Hynst J, Plevova K, Radova L, Bystry V, Pal K, Pospisilova S
PeerJ
. 2019 Jun;
7:e7071.
PMID: 31223530
Background: Extensive genome rearrangements, known as chromothripsis, have been recently identified in several cancer types. Chromothripsis leads to complex structural variants (cSVs) causing aberrant gene expression and the formation of...